Hepatocellular carcinoma
Conditions
Interventions
Modeling Exploration Group:None
Conventional Treatment Group:Targeted - Immunotherapy Combination Therapy + RECIST 1.1 Standard Adjustment Plan
AI-guided Intervention Group:Targeted-Immunotherapy Combination Therapy + AI Drug Resistance Warning Individualized Adjustment Plan
Sponsors
Guabgzhou First People‘s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years, gender not limited; 2.Pathologically confirmed unresectable hepatocellular carcinoma (uHCC), ECOG score 0-1, expected survival period >= 12 weeks; 3.Liver function Child-Pugh classification is Grade A or B; 4.No prior liver tumor resection, radiofrequency ablation, or radiotherapy; 5.Voluntarily sign the informed consent form and be willing to cooperate in completing all follow-up procedures;
Exclusion criteria
Exclusion criteria: 1.Complicated with systemic infection, autoimmune disease, or other types of malignant tumors; History of splenectomy; 2.Currently using immunomodulatory drugs such as interferon and interleukin; 3.Having contraindications for MRI examination such as cardiac pacemaker and magnetic metal implants in the body; 4.Pregnant or lactating women (women of childbearing age need to commit to contraception during the study period); 5.Severe hepatic and renal insufficiency (Cr clearance = 2.5 times the upper limit of normal); 6.History of splenectomy; 7.Other conditions judged by the researcher as unsuitable for inclusion (such as poor compliance, mental disorders, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-month progression-free survival rate (6-month PFS rate); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of ineffective treatment;Area Under Curve (AUC) of prediction model;Correlation between dynamic tumor hypoxia parameters and targeted-immunotherapy resistance;Specificity of AI drug resistance prediction model;Incidence rate of Grade =3 severe adverse events;Intraclass Correlation Coefficient (ICC) of multimodal radiomic features;Objective Response Rate (ORR);Sensitivity of AI drug resistance prediction model;12-month overall survival rate (12-month OS rate); | — |
Countries
China
Contacts
Public ContactWu Hongzhen
Guabgzhou First People‘s Hospital
Outcome results
None listed